Navigation Links
ImmunoVaccine Technologies Broadens Its Patent Protection to Japan
Date:8/5/2008

HALIFAX, Aug. 5 /PRNewswire/ - ImmunoVaccine Technologies Inc. (IVT), a vaccine development company, today announced receipt of patent approval from the Japanese Patent Office for its vaccine platform. The specific patent, Vaccines with enhanced immune response and methods for their preparation, claims broad exclusivity that an effective, long-term immune response to treat a disease can be produced using a vaccine comprising of an antigen, an adjuvant, vesicles known as liposomes, and a hydrophobic carrier.

"We have a novel technology that enhances vaccines dramatically, so receiving patent approval is important in protecting our competitive advantage," commented Dr. Marc Mansour, Vice President R&D at IVT.

Securing broad patent coverage is part of IVT's strategy to maximize the market potential of its VacciMax(R) platform in the largest pharmaceutical markets in the world; including the US, Europe, Canada, Australia and Japan. The company's VacciMax(R) technology is based on a novel approach to the use of liposomes in an oil emulsion. IVT has discovered that liposomes, stabilized in the VacciMax(R) technology, significantly enhance antibody production, creating a more rapid immune response, following a single vaccination. The responses are also long lasting, without requiring booster immunizations.

"The issuance of the patent in Japan complements the US and European patents for our vaccine platform technology," said Dr Randal Chase, President and CEO of IVT. "We are watching the growth of the Asian market, and patent coverage in Japan is an important step in contributing to the wide reach of our vaccine products."

About IVT

ImmunoVaccine Technologies Inc. is a private, clinical-stage, vaccine development company. Through its own biotech research, patented VacciMax(R) and DepoVax(TM) technologies, and collaborations with partners, IVT creates vaccines with the potential to help save and improve lives around the world.

In December 2007, IVT signed a binding MOU to acquire Pennsylvania-based Immunotope Inc. The acquisition enables IVT to create an entire pipeline of proprietary therapeutic cancer and infectious-disease specific vaccines. In January 2008, IVT licensed its technology to Pfizer Animal health, marking a pivotal step in achieving its vision of delivering breakthrough vaccines.

http://www.immunovaccine.com


'/>"/>
SOURCE ImmunoVaccine Technologies Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. ImmunoVaccine Technologies Congratulates Dr. Ramila Philip as One of PAs Best 50 Women in Business
2. ImmunoVaccine Technologies Patents DepoVax(TM) Vaccine Platform
3. ImmunoVaccine Technologies appoints the Honourable Michael Kirby as Chair
4. ImmunoVaccine Technologies Inc. Nears Phase I Clinical Trials with Completion of Scientific Advisory Board
5. Neurobiological Technologies Reports Receipt of $2.1 Million Royalty Payment for Quarterly Sales of Memantine
6. MaxWell Biocorporation, LLC, and International Medical Information Technologies, Inc., Announce Partnership
7. Senesco Technologies Announces Successful Completion of First Milestone Related to Agreement with Bayer CropScience
8. [video] Edward Spink, CEO of TurboSonic Technologies, Inc. Discusses Contract With Biofuel Producer in Exclusive Interview on WallSt.nets 3-Minute Press Show
9. Local officials move toward monitoring nanotechnologies
10. VNUS Medical Technologies to Present at BMO Capital Markets 2008 Focus on Healthcare Conference
11. China Medical Technologies Adjusts Conversion Rate of Convertible Notes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... DuPont Pioneer ... that they have entered into a multiyear collaboration to identify and characterize novel ... additional tools for gene editing across all applications. , Under the terms of ...
(Date:10/12/2017)... ... October 12, 2017 , ... BioMedGPS announces expanded ... of its newest module, US Hemostats & Sealants. , SmartTRAK’s US Market for ... fibrin sealants, synthetic sealants and biologic sealants used in surgical applications. BioMedGPS estimates ...
(Date:10/12/2017)... CA (PRWEB) , ... October ... ... (https://www.onramp.bio/ ) has launched Rosalind™, the first-ever genomics analysis platform specifically designed ... bioinformatics complexity. Named in honor of pioneering researcher Rosalind Franklin, who made ...
(Date:10/11/2017)... ... October 11, 2017 , ... The CRISPR-Cas9 ... overexpression experiments and avoiding the use of exogenous expression plasmids. The simplicity of ... performing systematic gain-of-function studies. , This complement to loss-of-function studies, such as ...
Breaking Biology Technology:
(Date:8/15/2017)... LLC , a medical device company focused on improving the safety ... ISO 13485 Certification, the global standard for medical device quality management ... ... for the early detection of IV infiltrations. ... "This is an important milestone for ivWatch, as it validates our ...
(Date:6/23/2017)... ITHACA, N.Y. , June 23, 2017 ... a leader in dairy research, today announced a new ... help reduce the chances that the global milk supply ... this dairy project, Cornell University has become the newest ... Food Supply Chain, a food safety initiative that includes ...
(Date:5/16/2017)... N.J. , May 16, 2017  Veratad Technologies, ... provider of online age and identity verification solutions, announced ... K(NO)W Identity Conference 2017, May 15 thru May 17, ... Regan Building and International Trade Center. ... the globe and in today,s quickly evolving digital world, ...
Breaking Biology News(10 mins):